Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sialic acid-binding Ig-like lectins (Siglecs) are a family of cell surface proteins that mediate interactions with sialylated glycoproteins and glycolipids, playing roles in immune regulation and cell signaling[2][4]. Sialic acid-binding Ig-like lectin 12 (SIGLEC12 or Siglec-XII) is a member of this family, with some functional alleles discussed in the literature (notably, functional SIGLEC12 is encoded by the SIGLEC12 gene, not a pseudogene)[4]. However, the entity ENSG00000268711 corresponds to a pseudogene—a non-functional remnant of SIGLEC12—which does not produce a functional protein product. Pseudogenes have lost protein-coding ability due to mutations and are generally not considered drug targets or relevant for direct therapeutic intervention. If you are interested in the therapeutic relevance of the functional SIGLEC12 protein, note that research indicates certain SIGLEC12 alleles may be linked to the progression of some carcinomas[4]. However, the majority of humans carry a SIGLEC12 allele that produces a non-functional version of the protein[4]. The pseudogene (ENSG00000268711) itself has no known biological or clinical significance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sialic acid-binding Ig-like lectin 12 pseudogene.